Newmont Deploys Drones and Remote-Controlled Scoop to Dig Out Trapped Miners
The drones are deployed to assess underground conditions while a remote-controlled scoop from the firm's Brucejack site has started removing debris from a blocked area, a Newmont spokesperson said Thursday in an emailed statement. A second collapse had cut off communication, but Newmont said the workers are understood to be sheltering in a refuge chamber designed to support 16 people.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
a minute ago
- Yahoo
Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW251, a Novel Glypican 3-Targeted Topoisomerase 1 Inhibitor Antibody-Drug Conjugate
Second antibody-drug conjugate (ADC) to progress into clinical development utilizing our proprietary payload and optimized antibody Preclinical results demonstrate strong anti-tumor activity and favorable tolerability profile Phase 1 clinical trial evaluating ZW251 in hepatocellular carcinoma (HCC) expected to be initiated in 2025 VANCOUVER, British Columbia, July 28, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, today announced the U.S. Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application for ZW251, a novel glypican-3 (GPC3)-targeted ADC incorporating the company's proprietary topoisomerase 1 inhibitor (TOPO1i) payload, ZD06519, for the treatment of HCC. HCC is the most common type of primary liver cancer, with GPC3 expressed in over 75% of cases1. ZW251 is a potential first-in-class ADC engineered to selectively target GPC3. It is composed of a humanized IgG1 antibody conjugated to a novel camptothecin-based TOPO1i using a validated peptide cleavable linker. A drug-antibody-ratio (DAR) of four was selected for ZW251 as a lower DAR potentially could unlock a broader range of dose levels, a potential benefit as HCC patients are commonly challenged by impairment of liver function as a result of chronic liver disease and cirrhosis. In preclinical studies, ZW251 demonstrated strong activity in a range of HCC models, including a range of patient derived xenografts exhibiting a breadth of GPC3 expression and noteworthy tolerability in non-human primate toxicology studies at doses up to 120 mg/kg. 'This advancement marks the second ADC from our wholly-owned pipeline, utilizing our proprietary TOPO1i payload, to progress into clinical development, reinforcing confidence in our approach,' said Paul Moore, Ph.D., Chief Scientific Officer of Zymeworks. 'Like ZW191, which is currently in clinical trials, ZW251 utilizes the same payload paired with an optimized antibody. Our observations with ZW191 in the clinic to date provide a strong foundation as we initiate clinical development of this second ADC. With its novel design, unique mechanism of action, and promising preclinical activity, ZW251 offers the potential to meaningfully improve upon the current standard of care for HCC either as a monotherapy or in combination.' We plan to commence Phase 1 clinical studies for ZW251 in 2025. About Zymeworks Inc. Zymeworks is a global clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, multifunctional biotherapeutics. Zymeworks' mission is to make a meaningful difference in the lives of people impacted by difficult-to-treat conditions such as cancer, inflammation, and autoimmune disease. The Company's complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop highly differentiated antibody-based therapeutic candidates. Zymeworks engineered and developed zanidatamab, a HER2-targeted bispecific antibody using the Company's proprietary Azymetric™ technology. Zymeworks has entered into separate agreements with BeOne Medicines Ltd. (formerly BeiGene, Ltd.) and Jazz Pharmaceuticals Ireland Limited, granting each exclusive rights to develop and commercialize zanidatamab in different territories. The U.S. FDA granted accelerated approval and China' s NMPA granted conditional approval for zanidatamab to treat adults with previously-treated, unresectable or metastatic HER2-positive (IHC 3+) biliary tract cancer. The European Commission (EC) has granted conditional marketing authorization for Ziihera® as monotherapy for the treatment of adults with unresectable locally advanced or metastatic HER2-positive (IHC 3+) biliary tract cancer previously treated with at least one prior line of systemic therapy. Zanidatamab is the first and only dual HER2-targeted bispecific antibody approved for HER2-positive biliary tract cancer in the U.S., Europe, and China. In addition, zanidatamab is being evaluated in multiple global clinical trials as a potential best-in-class treatment for patients with multiple HER2-expressing cancers. Zymeworks is rapidly advancing a robust pipeline of wholly-owned product candidates, leveraging its expertise in both antibody-drug conjugates and multispecific antibody therapeutics targeting novel pathways in areas of significant unmet medical need. Phase 1 studies for ZW171 and ZW191 are actively recruiting and ZW251 is expected to enter clinical trials in 2025. In addition to Zymeworks' pipeline, its therapeutic platforms have been further leveraged through strategic partnerships with global biopharmaceutical companies. For information about Zymeworks, visit and follow @ZymeworksInc on X. Cautionary Note Regarding Forward-Looking StatementsThis press release includes 'forward-looking statements' or information within the meaning of the applicable securities legislation, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements in this press release include, but are not limited to, statements that relate to the efficacy and safety of zanidatamab and Zymeworks' product candidates; ongoing clinical studies and regulatory reviews; the potential addressable market of zanidatamab and Zymeworks' product candidates; the timing of and results of interactions with regulators; Zymeworks' clinical development of its product candidates and enrollment in its clinical trials; the timing and status of ongoing and future studies, clinical trials and the related data; expectations regarding future regulatory filings and approvals and the timing thereof; potential safety profile and therapeutic effects of zanidatamab and Zymeworks' product candidates; and the commercial potential of technology platforms and product candidates. When used herein, words such as 'plan', 'believe', 'expect', 'may', 'anticipate', 'potential', 'will', 'intend', 'continues', 'progress', and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon Zymeworks' current expectations and various assumptions. Zymeworks believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. Zymeworks may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various factors, including, without limitation: clinical trials, including any required confirmatory trials, may not demonstrate safety and efficacy of any of Zymeworks' or its collaborators' product candidates; any of Zymeworks' or its partners' product candidates may fail in development, may not receive required regulatory approvals, or may be delayed to a point where they are not commercially viable; conditional regulatory approval may be withdrawn or revoked if any of Zymeworks' or its partners' product candidates fail to satisfy the requirements of any such conditional regulatory approvals; regulatory agencies may impose additional requirements or delay the initiation of clinical trials; the impact of new or changing laws and regulations; market conditions, including the impact of tariffs; potential negative impacts of FDA regulatory delays and uncertainty and new policies implemented under the current administration, including executive orders, changes in the leadership of federal agencies such as the FDA, staff layoffs, budget cuts to agency programs and research, and changes in drug pricing controls; the impact of pandemics and other health crises on Zymeworks' business, research and clinical development plans and timelines and results of operations, including impact on its clinical trial sites, collaborators, and contractors who act for or on Zymeworks' behalf; zanidatamab and Zymeworks' product candidates may not be successfully commercialized; clinical trials and any future clinical trials may not demonstrate safety and efficacy of any of Zymeworks' or its collaborators' product candidates; inability to maintain or enter into new partnerships or strategic collaborations; and the factors described under 'Risk Factors' in Zymeworks' quarterly and annual reports filed with the Securities and Exchange Commission (copies of which may be obtained at and Although Zymeworks believes that such forward-looking statements are reasonable, there can be no assurance they will prove to be correct. Investors should not place undue reliance on forward-looking statements. The above assumptions, risks and uncertainties are not exhaustive. Forward-looking statements are made as of the date hereof and, except as may be required by law, Zymeworks undertakes no obligation to update, republish, or revise any forward-looking statements to reflect new information, future events or circumstances, or to reflect the occurrences of unanticipated events. Contacts: Investor Inquiries:Shrinal InamdarSenior Director, Investor Relations(604) 678-1388ir@ Media Inquiries:Diana PapoveSenior Director, Corporate Communications(604) 678-1388media@ _______________________ 1 Wang HL et al., Arch Pathol Lab Med 2008.
Yahoo
a minute ago
- Yahoo
Bank of Canada expected to hold interest rates steady for the third time
By Promit Mukherjee OTTAWA (Reuters) -The Bank of Canada on Wednesday is likely to keep interest rates unchanged at 2.75% for the third time, economists and market analysts predict, as firm core inflation and robust job growth lessen the urgency to ease rates. The central bank, economists and businesses are increasingly hoping that the worst-case scenario from the impact of President Donald Trump's tariffs is over. "Core inflation is still a little bit hot for the Bank of Canada's comfort," said Doug Porter, chief economist at BMO Capital Markets. "And on top of that, most of the economic data we have seen in recent weeks and even months has been a little less bad than expected," he added, saying that the chances of a continued pause in rates are much more likely. The spillover effects from high tariffs on steel, aluminum and automobiles have largely been confined within those markets while other sectors posted job growth in June. The economy added 83,100 new jobs in June, the first net increase since January. The unemployment rate fell to 6.9% in June with surprise job growth in sectors including wholesale and retail trade, as well as manufacturing, healthcare and social assistance. At the same time, the core measures of inflation that the BoC closely tracks have been persistently at or above 3%, the upper end of the bank's 1%-3% inflation target range. "The Bank of Canada, being a single mandate central bank, cares about inflation the most," said David Doyle, head of economics at Macquarie. Money markets are pricing in a 7%-8% probability of a rate cut this week. A Reuters poll of 28 economists showed that the lack of clarity around tariffs, combined with recent data on inflation and jobs, will keep the BoC on the sidelines this week. The poll was conducted from July 21 to July 25. Nearly two-thirds of the economists surveyed, 18 of 28, forecast that the BoC would cut its policy rate by 25 basis points in September to 2.50%. More than 60% of the economists predicted a second 25-bps cut before yearend. The BoC was the first central bank among the G7 countries to start cutting rates in June last year and has been the most aggressive since then in its easing cycle. It has reduced rates by 225 basis points between June last year and March. BoC Governor Tiff Macklem will announce the governing council's decision at 9:45 a.m. ET (1345 GMT) on Wednesday. The bank will also release its quarterly monetary policy report, which usually contains its predictions on the economy and inflation. However, the BoC changed tack in April for the first time since the pandemic and offered two different scenarios for the economy as uncertainty on the magnitude and the timing of tariffs have complicated forecasting, the bank said. "Things are still tremendously uncertain, but it feels like the uncertainty has come down a little bit since then. I would be surprised if they didn't present formal forecasts," Doyle from Macquarie said. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
New York Times
4 minutes ago
- New York Times
Blue Jays trade deadline notes: Future rotation depth, controllable relievers, and more
Over time, general managers build reputations, developing specific niches for which they're known. Seattle's Jerry Dipoto has his constant stream of trades. For San Diego's A.J. Preller, it's star splashes. Atlanta's Alex Anthopoulos locks up young players to long-term deals. Nine years into his tenure as Toronto Blue Jays general manager, Ross Atkins' niche might be long-term pitching moves at the trade deadline. He has overseen four clear buying deadlines in Toronto. In each of those, the Jays acquired at least one controllable pitcher — five starters and four relievers with multiple years remaining. It's not always a closer or ace, with quality ranging from Mike Bolsinger to José Berríos, but there's a clear playbook Atkins could return to this week. Advertisement 'For individuals who could be here for extended periods of time,' Atkins said after the 2022 deadline. 'We've seen huge benefits in that, the continuity of guys being together.' After winning a series against the Detroit Tigers over the weekend, the Jays sit with the best record in baseball, 63-43. Things are clicking, but the upcoming trade deadline presents a final opportunity to bolster the team ahead of October. Atkins discussed the need for a bat earlier this summer, and the Jays, per a league source, are turning over every stone in the relief market. But with Chris Bassitt and Max Scherzer set for free agency in the offseason, the Jays could, once again, build depth for the 2025 rotation while filling open holes beyond. Here are a few long-term options who could be available this week. Joe Ryan, Edward Cabrera and Sandy Alcántara are the biggest fish in this controllable pool, all under team control for at least two seasons after 2025 with top-of-rotation upside. Jeffrey Springs is a particularly interesting fit in the lower tier. He has a 4.13 ERA on the season and 4.01 mark away from Sacramento, projecting as a mid- or back-of-rotation lefty. He may not be an immediate upgrade in Toronto's rotation, but with 110 career relief appearances (including two follower outings this year), Springs could join the bullpen and act as 2025 depth before rejoining the Jays' starting staff next year. He's owed $10.5 million next year with a $15 million club option for 2027. Another long-term starter who should be available is Athletics righty Luis Severino. While the veteran expressed dissatisfaction with the Sacramento set up, and his road splits are much better, Severino isn't missing bats at all this season. He has a 4.95 ERA and a 4.53 expected mark. The 31-year-old is owed $25 million next season and holds a $22 million player option for 2027. Advertisement The A's are actively listening on Severino, but a deal might be difficult to pull off, a league source said, as the organization isn't seen as willing to retain large portions of any contract. They sent cash with J.D. Davis in a trade to the Yankees in 2024, but that was just $927,312. There are few other examples of the A's moving cash alongside players in recent history. Toronto could also bolster the bullpen with long-term additions at this deadline. Cleveland's Emmanuel Clase (under team control through 2028) and Minnesota's Jhoan Duran and Griffin Jax (both arbitration eligible through 2027) are big-swing relief options. The Rockies are another team to watch for bullpen help. Colorado is perceived to be engaging in trade talk in a way that opposing teams haven't seen at previous deadlines. Ryan McMahon went to the Yankees over the weekend, but the Rockies also have controllable relievers such as Jimmy Herget, Seth Halvorsen and Jake Bird to deal. The Jays entered the 2025 season resting 24th in Keith Law's farm system rankings. While the system is still seen as sitting in the back half of baseball, it made strides in 2025, equipping Toronto with rising prospects to move this week. Multiple opposing scouts attended Vancouver Canadians games last week. The biggest name with Toronto's High-A affiliate is shortstop Arjun Nimmala, but the Canadians also roster rising starter Gage Stanifer. Infielder Cutter Coffey and catcher Edward Duran could also draw attention. Top pitching prospect Trey Yesavage threw four perfect innings on Saturday, striking out five batters. It was his first outing in 20 days, with one batter faced at the 2025 Futures Game in between. The pause was an intentional break to manage Yesavage's workload, with the righty currently at 71 innings pitched. He could get up to 110 to 130 innings this year and this midseason pause will allow him to pitch through September — whether that's with New Hampshire, Buffalo or Toronto. (Top photo of Ross Atkins: Mark Blinch / Getty Images)
